Browse TIGIT

Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF07686 Immunoglobulin V-set domain
Function

Binds with high affinity to the poliovirus receptor (PVR) which causes increased secretion of IL10 and decreased secretion of IL12B and suppresses T-cell activation by promoting the generation of mature immunoregulatory dendritic cells.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0002683 negative regulation of immune system process
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules
GO:0007157 heterophilic cell-cell adhesion via plasma membrane cell adhesion molecules
GO:0007159 leukocyte cell-cell adhesion
GO:0007162 negative regulation of cell adhesion
GO:0008037 cell recognition
GO:0022407 regulation of cell-cell adhesion
GO:0022408 negative regulation of cell-cell adhesion
GO:0032613 interleukin-10 production
GO:0032615 interleukin-12 production
GO:0032653 regulation of interleukin-10 production
GO:0032655 regulation of interleukin-12 production
GO:0032695 negative regulation of interleukin-12 production
GO:0032733 positive regulation of interleukin-10 production
GO:0042110 T cell activation
GO:0050863 regulation of T cell activation
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050868 negative regulation of T cell activation
GO:0051249 regulation of lymphocyte activation
GO:0051250 negative regulation of lymphocyte activation
GO:0070486 leukocyte aggregation
GO:0070489 T cell aggregation
GO:0071593 lymphocyte aggregation
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules
GO:1903037 regulation of leukocyte cell-cell adhesion
GO:1903038 negative regulation of leukocyte cell-cell adhesion
Molecular Function GO:0050839 cell adhesion molecule binding
Cellular Component GO:0005913 cell-cell adherens junction
> KEGG and Reactome Pathway
 
KEGG hsa04514 Cell adhesion molecules (CAMs)
Reactome -
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TIGIT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between TIGIT and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26763253Acute Myeloid LeukemiaInhibit immunity (T cell function)TIGIT contributes to functional T-cell impairment and associates with poor clinical outcome in AML.
25680274Colorectal CarcinomaInhibit immunity (NK cell function)We have further demonstrated that tumor-infiltrating lymphocytes expressed TIGIT and that T cell activities were also inhibited by F. nucleatum via Fap2.
23536636MelanomaInhibit immunity (T cell function); essential for immunotherapyConcomitantly, tumor-specific CD4(+) T effector cells showed traits of chronic exhaustion, as evidenced by their high expression of the PD-1, TIM-3, 2B4, TIGIT, and LAG-3 inhibitory molecules. Although blockade of the PD-1/PD-L1 pathway with anti-PD-L1 Abs or depletion of tumor-specific regulatory T cells (Tregs) alone failed to reverse tumor recurrence, the combination of PD-L1 blockade with tumor-specific Treg depletion effectively mediated disease regression.
29217528Follicular LymphomaInhibit immunityCD8 FL T cells demonstrated highly reduced TCR-induced phosphorylation (p) of ERK and reduced production of IFNγ, while TCR proximal signaling (p-CD3ζ, p-SLP76) was not affected. Dysfunctional TCR signaling correlated with TIGIT expression in FL CD8 T cells and could be fully restored upon in vitro culture.
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TIGIT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TIGIT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1440.801
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.060.957
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.2970.752
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.060.847
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2880.775
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.2260.856
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.8170.025
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.7050.0336
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.9140.502
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.1720.228
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8370.559
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0590.805
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TIGIT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.1011.10.0181
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.1011.10.0286
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38277.907.90.26
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.109.10.519
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16146.206.21
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TIGIT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TIGIT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TIGIT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TIGIT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TIGIT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TIGIT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTIGIT
NameT cell immunoreceptor with Ig and ITIM domains
Aliases FLJ39873; DKFZp667A205; VSIG9; VSTM3; V-set and immunoglobulin domain containing 9; V-set and transmembrane ......
Chromosomal Location3q13.31
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TIGIT collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.